Home
World Journal of Biology Pharmacy and Health Sciences
ISSN Approved | International, Peer reviewed, Referred, Open access Journal

Main navigation

  • Home
    • Journal Information
    • Abstracting and Indexing
    • Editorial Board Members
    • Reviewer Panel
    • Journal Policies
    • WJBPHS CrossMark Policy
    • Publication Ethics
    • Current Issue
    • Issue in Progress
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Become a Reviewer panel member
    • Join as Editorial Board Member
  • Contact us
  • Downloads

ISSN Approved Journal | | IMPACT FACTOR 8.16 | | eISSN: 2582-5542 | |  Free Crossref DOI 

Fast Publication within 2 days | | Low Article Processing Charges | | Peer Reviewed and Referred Journal

Research and review articles are invited for publication in September 2026 (Volume 27, Issue 3) Submit Paper

Antiphospholipid syndrome: Autoimmunity and thrombosis

Breadcrumb

  • Home
  • Antiphospholipid syndrome: Autoimmunity and thrombosis

Dr. Pasupuleti Kishore Kumar 1, *, Thokala Ruchitha 2, Pasumala Varun 2, Chinta Rohit Kumar 2 and Dr. Tadikonda Rama Rao 3

1 Department of PharmD, CMR College of Pharmacy, Hyderabad, India.
2 Students, Department of PharmD, CMR College of Pharmacy, Hyderabad, India.
3 Principal, CMR College of Pharmacy, Hyderabad, India.
 

Review Article

World Journal of Biology Pharmacy and Health Sciences, 2025, 22(03), 602–605

Article DOI: 10.30574/wjbphs.2025.22.3.0601

DOI url: https://doi.org/10.30574/wjbphs.2025.22.3.0601

Received on 06 May 2025; revised on 13 June 2025; accepted on 16 June 2025

The rare systemic autoimmune disease known as antiphospholipid syndrome (APS) is typified by persistent antiphospholipid antibodies (aPL) along with obstetric morbidity, recurrent thrombosis in the veins and/or arteries, and other non-thrombotic related complications. Obesity, diabetes, hypertension, and cardiovascular diseases are among the long-term health problems that children from difficult pregnancies may be more susceptible to, which could impact their wellbeing both during childhood and into adulthood. Antiphospholipid antibodies' precise etiology is unknown. Being an autoimmune disease, APS causes antibodies to target healthy molecules such as phospholipids, which interferes with coagulation and makes the patient more prone to thrombophilia. The cornerstones of the current preventative treatment standard for APS are anticoagulation and antiplatelet therapy. One significant preventable cause of early pregnancy loss is APS. Preventing obstetric complications requires early risk assessment and individualized treatment, which may include vitamin D, folic acid, and aspirin.

Autoimmune disease; Thrombophilia; Antiphospholipid antibodies (aPL); Coagulation; Obstetric complications

https://wjbphs.com/sites/default/files/fulltext_pdf/WJBPHS-2025-0601.pdf

Preview Article PDF

Dr. Pasupuleti Kishore Kumar, Thokala Ruchitha, Pasumala Varun, Chinta Rohit Kumar, Dr. Tadikonda Rama Rao. Antiphospholipid syndrome: Autoimmunity and thrombosis. World Journal of Biology Pharmacy and Health Sciences, 2025, 22(03), 602-605; Article DOI: https://doi.org/10.30574/wjbphs.2025.22.3.0601.

Get Certificates

Get Publication Certificate

Download LoA

Check Corssref DOI details

Issue details

Issue Cover Page

Editorial Board

Table of content


Copyright © Author(s). All rights reserved. This article is published under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as appropriate credit is given to the original author(s) and source, a link to the license is provided, and any changes made are indicated.


Copyright © 2026 World Journal of Biology Pharmacy and Health Sciences (WJBPHS) - All rights reserved

Developed & Designed by VS Infosolution